Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABCZF OTCMKTS:ATTBF OTCMKTS:EPRSQ OTCMKTS:FFNTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shs7,500 shsEPRSQEPIRUS Biopharmaceuticals$0.00$0.00▼$0.00N/AN/AN/AN/AFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.28 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%EPRSQEPIRUS Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%FFNTF4Front Ventures0.00%0.00%0.00%0.00%-97.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shs7,500 shsEPRSQEPIRUS Biopharmaceuticals$0.00$0.00▼$0.00N/AN/AN/AN/AFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.28 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%EPRSQEPIRUS Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%FFNTF4Front Ventures0.00%0.00%0.00%0.00%-97.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCZFAbcam 0.00N/AN/AN/AATTBFAbattis Bioceuticals 0.00N/AN/AN/AEPRSQEPIRUS Biopharmaceuticals 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCZFAbcamN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCZFAbcamN/AC$0.17130.73N/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/A-$0.16N/AN/AN/AN/AN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCZFAbcamC$0.070.32%N/A42.48%N/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCZFAbcam43.58%ATTBFAbattis Bioceuticals32.45%EPRSQEPIRUS BiopharmaceuticalsN/AFFNTF4Front VenturesN/AInsider OwnershipCompanyInsider OwnershipABCZFAbcamN/AATTBFAbattis BioceuticalsN/AEPRSQEPIRUS Biopharmaceuticals13.06%FFNTF4Front VenturesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCZFAbcam1,750N/AN/ANot OptionableATTBFAbattis BioceuticalsN/AN/AN/ANot OptionableEPRSQEPIRUS Biopharmaceuticals70N/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableEPRSQ, FFNTF, ATTBF, and ABCZF HeadlinesRecent News About These CompaniesCSE Bulletin: Delist - 4Front Ventures Corp. (FFNT)January 16, 2026 | newsfilecorp.comNBelly-up weed company puts 3 Chicago-area shops, massive grow facility up for saleAugust 14, 2025 | chicagobusiness.comC2 board members, including Kris Krane, resign from marijuana operator 4FrontJune 30, 2025 | mjbizdaily.comM4Front Ventures Provides Update on Receivership Proceedings and Board ResignationsJune 26, 2025 | prnewswire.comCannabis company 4Front Ventures files for bankruptcy in CanadaJune 14, 2025 | mjbizdaily.comM4Front Ventures initiates bankruptcy proceedings in CanadaJune 12, 2025 | investing.com4Front Ventures initiates bankruptcy proceedings in CanadaJune 12, 2025 | investing.com4Front Ventures declares bankruptcyJune 12, 2025 | uk.investing.com4Front Ventures Files for Bankruptcy ProtectionJune 10, 2025 | tipranks.com4Front Initiates Bankruptcy and Insolvency Act Proceedings in CanadaJune 10, 2025 | prnewswire.com4Front Ventures shifts to OTC Pink MarketMay 29, 2025 | investing.com4Front Ventures Files for Receivership in MassachusettsMay 27, 2025 | tipranks.comMarijuana operator 4Front files for receivershipMay 23, 2025 | mjbizdaily.comM4Front Ventures Places US-Based Subsidiaries Into ReceivershipMay 23, 2025 | thedeepdive.caT4Front Ventures Files for Receivership Amid Financial StrugglesMay 23, 2025 | tipranks.comAll 4Front Subsidiaries File for Court-Appointed ReceiverMay 23, 2025 | prnewswire.comOntario Securities Commission Issues Failure-to-File Cease Trade Order Against 4FrontMay 8, 2025 | prnewswire.com4Front Ventures Faces Cease Trade Order Due to Filing DelaysApril 24, 2025 | tipranks.com4Front Provides Update on MCTO ApplicationApril 24, 2025 | prnewswire.com4Front Ventures delays annual filings, can’t pay auditorsApril 17, 2025 | greenmarketreport.comGNew MarketBeat Followers Over TimeEPRSQ, FFNTF, ATTBF, and ABCZF Company DescriptionsAbcam OTCMKTS:ABCZFC$22.25 0.00 (0.00%) As of 05/4/2026Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.Abattis Bioceuticals OTCMKTS:ATTBFAbattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.EPIRUS Biopharmaceuticals OTCMKTS:EPRSQEPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.4Front Ventures OTCMKTS:FFNTF4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
